References
- Alvarnas JC, Brown PA, Aoun P, et al (2012). Acute lymphoblastic leukemia. J Natl Compr Canc Netw, 10, 858-914. https://doi.org/10.6004/jnccn.2012.0089
- Alvarnas JC, Brown PA, Aoun P, et al (2015). Acute lymphoblastic leukemia. J Natl Compr Canc Netw, 13, 1240-79. https://doi.org/10.6004/jnccn.2015.0153
- Asselin BL, Ryan D, Frantz CN, et al (1989). In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res, 49, 4363-8.
- Earl M (2009). Incidence and management of asparaginaseassociated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol, 7, 600-6.
- Grace RF, Dahlberg SE, Neuberg D, et al (2011). The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on dana-farber cancer institute consortium protocols. Br J Haematol, 152, 452-9. https://doi.org/10.1111/j.1365-2141.2010.08524.x
- Kafkewitz D and Bendich A (1983). Enzyme-induced asparagine and glutamine depletion and immune system function. Am J Clin Nutr, 37, 1025-30. https://doi.org/10.1093/ajcn/37.6.1025
- Kfoury-Baz EM, Nassar RA, Tanios RF, et al (2008). Plasmapheresis in asparaginase-induced hypertriglyceridemia. Transfusion, 48, 1227-30. https://doi.org/10.1111/j.1537-2995.2008.01663.x
- Liu C, Kawedia JD, Cheng C, et al (2012). Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia, 26, 2303-9. https://doi.org/10.1038/leu.2012.102
- Nakagawa M, Kimura S, Fujimoto K, et al (2008). A case report of an adult with severe hyperlipidemia during acute lymphocytic leukemia induction therapy successfully treated with plasmapheresis. Ther Apher Dial, 12, 509-13. https://doi.org/10.1111/j.1744-9987.2008.00647.x
- Narta UK, Kanwar SS and Azmi W (2007). Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Crit Rev Oncol Hematol, 61, 208-21. https://doi.org/10.1016/j.critrevonc.2006.07.009
- National Cancer Institute (2009). Common Terminology Criteria for Adverse Events v4.0. NIH publication # 09-7473.
- Oettgen HF, Stephenson PA, Schwartz MK, et al (1970). Toxicity of E. coli L-asparaginase in man. Cancer, 25, 253-78. https://doi.org/10.1002/1097-0142(197002)25:2<253::AID-CNCR2820250204>3.0.CO;2-U
- Parsons SK, Skapek SX, Neufeld EJ, et al (1997). Asparaginaseassociated lipid abnormalities in children with acute lymphoblastic leukemia. Blood, 89, 1886-95.
- Seah J, Lin K, Tai D, et al (2012). Conservative management of L-asparaginase-induced hypertriglyceridemia in an adult patient: a case report and review of the literature. Onkologie, 35, 596-8. https://doi.org/10.1159/000342690
- Steinherz PG (1994). Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase. Cancer, 74, 3234-9. https://doi.org/10.1002/1097-0142(19941215)74:12<3234::AID-CNCR2820741224>3.0.CO;2-1
- Stock W, Douer D, DeAngelo DJ, et al (2011). Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma, 52, 2237-53. https://doi.org/10.3109/10428194.2011.596963
- Truelove E, Fielding AK and Hunt BJ (2013). The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia, 27, 553-559. https://doi.org/10.1038/leu.2012.290
- Wang B, Relling MV, Storm MC, et al (2003). Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia, 17, 1583-8. https://doi.org/10.1038/sj.leu.2403011
- Yamaguchi M, Suzuki R, Kwong YL, et al (2008). Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci, 99, 1016-20. https://doi.org/10.1111/j.1349-7006.2008.00768.x
- Yamaguchi M, Suzuki R, Kim WS, et al (2011). Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol, 29, 4410-6. https://doi.org/10.1200/JCO.2011.35.6287
- Yong W, Zheng W, Zhang Y, et al (2003). L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol, 78, 163-7. https://doi.org/10.1007/BF02983387
- Zalewska-Szewczyk B, Gach A, Wyka K, et al (2009). The crossreactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med, 9, 113-6. https://doi.org/10.1007/s10238-008-0026-9